These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 19859084)

  • 1. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy.
    Han JY; Lee GK; Yoo SY; Yoon SJ; Cho EY; Kim HT; Lee JS
    Pharmacogenomics J; 2010 Apr; 10(2):86-93. PubMed ID: 19859084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between
    Yi J; Wang Y; Li Q; Zhang H; Shao Z; Deng X; He J; Xiao C; Wang Z; Wang Y; Chen C
    J Vet Sci; 2019 Sep; 20(5):e54. PubMed ID: 31565897
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
    Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade.
    Dünnebier T; Bermejo JL; Haas S; Fischer HP; Pierl CB; Justenhoven C; Brauch H; Baisch C; Gilbert M; Harth V; Spickenheuer A; Rabstein S; Pesch B; Brüning T; Ko YD; Hamann U
    Int J Cancer; 2009 Aug; 125(3):596-602. PubMed ID: 19358266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk.
    Dünnebier T; Bermejo JL; Haas S; Fischer HP; Pierl CB; Justenhoven C; Brauch H; Baisch C; Gilbert M; Harth V; Spickenheuer A; Rabstein S; Pesch B; Brüning T; Ko YD; Hamann U
    Breast Cancer Res Treat; 2010 May; 121(1):185-94. PubMed ID: 19760037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer.
    Han JY; Shin ES; Lee YS; Ghang HY; Kim SY; Hwang JA; Kim JY; Lee JS
    Pharmacogenomics J; 2013 Oct; 13(5):417-22. PubMed ID: 22664479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
    Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
    Gao H; Ge RC; Liu HY; Wang Y; Yan S
    Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Park YH; Lee SY; Lee JS
    Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy.
    Masago K; Togashi Y; Fujita S; Nagai H; Sakamori Y; Okuda C; Kim YH; Mishima M
    Oncology; 2013; 84(4):214-8. PubMed ID: 23364242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53.
    Lin JY; Ohshima T; Shimotohno K
    FEBS Lett; 2004 Aug; 573(1-3):15-8. PubMed ID: 15327968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
    Krawczyk P; Wojas-Krawczyk K; Mlak R; Kucharczyk T; Biernacka B; Milanowski J
    Folia Histochem Cytobiol; 2012 Apr; 50(1):80-6. PubMed ID: 22532140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.